“Personalised medicine and Big Pharma need bioinformatics”

David Searls retired three years ago from his position as senior Vice President of Bioinformatics in GlaxoSmithKline. Since then, this computer scientist who spent 16 years in academia and 19 years in industry has gone back to his theoretical studies on linguistic analysis of biological sequences. He was invited to the PRBB and talked to us about drugs and computers. This interview was published in Ellipse, the monthly magazine of the PRBB. What part does bioinformatics have in drug development?  It is an essential step along the way. This is because not only drug discovery, but all biology, has become, since the … Continue reading “Personalised medicine and Big Pharma need bioinformatics”

“Habitual competitors are now working together to get better toxicity predictions”

Ferran Sanz (IMIM-UPF) tells us about the eTOX project in a recent interview published in El·lipse, the monthly PRBB publication. The electronic toxicology project (eTOX) started in January 2010 as one of the projects funded in the first call of the IMI (Innovative Medicines Initiative), a unique public-private partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Ferran Sanz, director of the Research Programme on Biomedical Informatics (GRIB, IMIM-UPF) and academic coordinator of eTOX, evaluates the project’s achievements so far as very positive. What exactly is eTOX about? All IMI projects, including eTOX, bring … Continue reading “Habitual competitors are now working together to get better toxicity predictions”